Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Matthew C. Nicholson has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Andre Mattman

    Department of Pathology and Laboratory Medicine University of British Columbia Vancouver Canada

    1 shared publication
  • Anna R. Hayden

    Division of Hematology, Department of Medicine University of British Columbia Vancouver BC Canada

    1 shared publication
  • David Dix

    Division of Hematology, Oncology and Bone Marrow Transplant, Department of Paediatrics University of British Columbia Vancouver BC Canada

    1 shared publication
  • Jeffrey S. Ginsberg

    Division of Hematology and Thromboembolism, Department of Medicine, McMaster University, Hamilton, ON L8N 3Z5, Canada

    1 shared publication
  • Leonie Naeije

    Division of Hematology, Oncology and Bone Marrow Transplant, Department of Paediatrics University of British Columbia Vancouver BC Canada

    1 shared publication
  • Luke Y. C. Chen

    Division of Hematology University of British Columbia Vancouver British Columbia Canada

    1 shared publication

Latest Publications

  • Open Access

    Prevention of Venous Thromboembolism in 2020 and Beyond

    by Matthew Nicholson, Noel Chan, Vinai Bhagirath, Jeffrey Ginsberg

    Venous thromboembolism (VTE) is the third most common cause of vascular mortality worldwide and comprises deep-vein thrombosis (DVT) and pulmonary embolism (PE). In this review, we discuss how an understanding of VTE epidemiology and the results of thromboprophylaxis trials have shaped the current approach to VTE prevention. We will discuss modern thromboprophylaxis as it pertains to genetic risk factors, exogenous hormonal therapies, pregnancy, surgery, medical hospitalization, cancer, and what is known thus far about VTE in COVID-19 infection.


  • Open Access

    Etoposide‐based treatment of adult HLH is associated with high biochemical response but poor survival outcomes

    by Matthew C. Nicholson, Leonie Naeije, Anna R. Hayden, Andre Mattman, David Dix, Luke Y.C. Chen

    Etoposide‐based treatment is the standard of care for adult HLH in many centers, yet there remains a paucity of data regarding treatment outcomes. We conducted a retrospective study of 23 adults treated with etoposide‐based therapy compared to 10 pediatric HLH cases at a single center. At diagnosis, the median serum ferritin was 20,071 µg/L and 937 µg/L in adults and children, respectively; median sIL‐2r was 14,524 U/mL and 4,478 U/mL. Biochemical response to treatment was high, with 21/23 adults achieving >75% reduction in serum ferritin, but one year survival was only 7/21 compared to 7/10 in pediatric cases.